NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative delivery platform, DehydraTECH™, has demonstrated excellent results in delivery of nicotine to the brain in a recent lab study. An article discussing this reads, “The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (http://nnw.fm/oN1Xp). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s, schizophrenia and depression, it is now theorized that DehydraTECH could offer similar delivery advantages.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer